Sciclone Pharmaceuticals, Inc. (SCLN) Misses Q3 EPS by 1c; Lowers FY12 Outlook

Sciclone Pharmaceuticals, Inc. (NASDAQ: SCLN) reported Q3 EPS of $0.20, $0.01 worse than the analyst estimate of $0.21. Revenue for the quarter came in at $40.7 million versus the consensus estimate of $44.8 million.

Sciclone Pharmaceuticals, Inc. sees FY2012 EPS of $0.62-0.68, versus prior guidance of $0.72-0.78 and the consensus of $0.75. Sciclone Pharmaceuticals, Inc. sees FY2012 revenue of $152-157 million, versus prior guidance of $165-170 million and the consensus of $171.68 million.

For earnings history and earnings-related data on Sciclone Pharmaceuticals, Inc. (SCLN) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Top AI Semiconductor Stocks According to Stifel Analysis
• Jet fuel prices near $5 per gallon in New York and Los Angeles
• TD Cowen on Pepsico (PEP): 'Ongoing Weakness in North America Drives Guidance Cut'